Simplicity and Efficacy of a Once-Daily Antiretroviral Regimen with Didanosine, Lamivudine, and Efavirenz in Naïve Patients: The VESD Study

REFERENCES

• Powderly WG. Sorting through confusing messages: the art of HAART. J Acquir Immune Defic Syndr. 200231:S3–S9.
   Google Scholar
• Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS. 2001;15:1369–1377.
   PubMed Web of Science ®Google Scholar
• Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81–87.
   PubMed Web of Science ®Google Scholar
• Moyle G. Once-daily therapy: less is more. Int J STD AIDS. 2003;14\(suppl 1):1–5.
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Ripamonti D, Suter F. Once-a-day HAART: dream or reality? HIV Clin Trials. 2003;4: 193–201.
   PubMed Web of Science ®Google Scholar
• Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004;292:251–265.
   PubMed Web of Science ®Google Scholar
• Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, et al. Pharma-cokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin PharmacokineL 2002;41:681–690.
   Google Scholar
• Knobel H, Alonso J, Casado JL, et al. GEEMA Study Group Validation of a simplified medication adherence question-naire in a large cohort of HIV-infected patients: the GEEMA Study. AIDS. 2002;16:605–613.
   PubMed Web of Science ®Google Scholar
• Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res. 1997;6:481–493.
   PubMed Web of Science ®Google Scholar
• Callas EJ, Garcia FJ, Andérica G. Epidemiologia de la infecci6n por el VIH y sida. In: Pach6n J, Pujol E, Rivero A. La infecci6n por el VIH. Guia préctica. 2° ed. Sevilla: SAEI; 2003:37–54.
   Google Scholar
• Matthews GV, Sabin CA, Mandalia S, Lampe F, Phillips AN, Nelson MR. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS. 2002;16:53–61.
   PubMed Web of Science ®Google Scholar
• Friedl AC, Ledergerber B, Flepp M, et al. Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study. AIDS. 200115:1793–1800.
   Google Scholar
• Yazdanpanah Y, Sissoko D, Egger M, Mouton Y, Zwahlen M, Chene G. Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect compari-son of controlled trials. Br Med J. 2004;328:249–256.
   PubMed Web of Science ®Google Scholar
• Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999;341:1865–1873.
   PubMed Web of Science ®Google Scholar
• Lucas GM, Chaisson RE, Moore RD. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz. AIDS. 2001;15:1679–1686.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Staszewski S, Pozniak AL, et al. 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191–201.
   PubMed Web of Science ®Google Scholar
• Saag MS, Cahn P, Raffi F, et al. FTC-301 Study Team. Efficacy and safety of emtricitabine vs stavudine in combi-nation therapy in antiretroviral-naive patients: a randomized trial. JAMA. 2004;292:180–189.
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Migliorino M, Maserati R, et al. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Once Study Group. Antivir 777er. 2001;6:249–253.
   Google Scholar
• Maggiolo F, Ripamonti D, Gregis G, et al. Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients. Antivir Ther. 2003;8:339–346.
   PubMed Web of Science ®Google Scholar
• Landman R, Schiemann R, Thiam S, et al. Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal. AIDS. 2003;17:1017–1022.
   PubMed Web of Science ®Google Scholar
• Molina JM, Ferchal F, Rancinan C, Raffi F, Rozenbaum W, Sereni D. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immuno-deficiency virus-infected patients. J Infect Dis. 2000; 182:599–602.
   PubMed Web of Science ®Google Scholar
• Arribas JR, Pulido F, Miro JM, et al. High effectiveness of efavirenz-based highly active antiretroviral therapy in H IV-1-infected patients with fewer than 100 CD4 cells/microl and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients) and the EfaVIP Cohort Study Group. AIDS. 2002;16:1554–1556.
   PubMed Web of Science ®Google Scholar
• Pulido F, Arribas JR, Miro J, et al. The EfaVIP Cohort Study Group clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive pa-tients with advanced HIV infection (EfaVIP 2 Study). J Acquir Immune Defic Syndr. 2004;35:343–350.
   PubMed Web of Science ®Google Scholar
• Santos J, Palacios R, Ruiz J, Gonzélez M, Marquez M. Study of patients diagnosed with advanced HIV in the HAART era. OMEGA Cohort. Int J STD AIDS. 2005;16:252–255.
   PubMed Web of Science ®Google Scholar
• Perez-Molina JA. Safety and tolerance of efavirenz in differ-ent antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected pa-tients. HIV Clin Trials. 2002;3:279–286.
   PubMedGoogle Scholar
• Clarke SM, Mulcahy FM, Tjia J, et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. BrJ Clin PharmacoL 200151: 213–217.
   Google Scholar
• Reynolds NR, Testa MA, Marc LG, et al. Factors influencing medication adherence beliefs and self-efficacy in persons naive to antiretroviral therapy: a multicenter, cross-sectional study. AIDS Behav. 2004;8:141–150.
   PubMed Web of Science ®Google Scholar
• Moyle G. The assessing patients' preferred treatments (APPT-1) study. Int J STD AIDS. 2003;14\(suppl 1):34–36.
   PubMed Web of Science ®Google Scholar